Wynnefield Capital’s Lifecore Biomedical LFCR Stock Holding History

Wynnefield Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.5M	Hold	4,703,216	–	–	11.86%	4
2025 Q4	$38.5M	Hold	4,703,216	–	–	21.63%	3
2025 Q3	$34.6M	Hold	4,703,216	–	–	20.8%	3
2025 Q2	$38.2M	Hold	4,703,216	–	–	22.53%	1
2025 Q1	$33.1M	Hold	4,703,216	–	–	20.95%	2
2024 Q4	$34.9M	Sell	4,703,216 -215,763	-4%	-$1.38M	15.93%	4
2024 Q3	$24.3M	Hold	4,918,979	–	–	10.79%	5
2024 Q2	$25.2M	Sell	4,918,979 -4,566	-0.1%	-$27K	11.34%	5
2024 Q1	$26.1M	Hold	4,923,545	–	–	10.39%	5
2023 Q4	$30.5M	Hold	4,923,545	–	–	11.78%	4
2023 Q3	$37.1M	Hold	4,923,545	–	–	17.04%	4
2023 Q2	$47.6M	Hold	4,923,545	–	–	23.8%	1
2023 Q1	$18.6M	Buy	4,923,545 +461,035	+10%	+$2.57M	12.04%	4
2022 Q4	$28.9M	Buy	4,462,510 +929,223	+26%	+$7.66M	16.63%	3
2022 Q3	$31.4M	Hold	3,533,287	–	–	16.57%	3
2022 Q2	$35.2M	Hold	3,533,287	–	–	17.8%	2
2022 Q1	$40.9M	Buy	3,533,287 +387,400	+12%	+$4.31M	15.62%	3
2021 Q4	$34.9M	Hold	3,145,887	–	–	12.47%	4
2021 Q3	$29M	Hold	3,145,887	–	–	15.66%	3
2021 Q2	$35.4M	Buy	3,145,887 +240,587	+8%	+$2.77M	16.32%	4
2021 Q1	$30.7M	Buy	2,905,300 +20,000	+0.7%	+$225K	15.27%	3
2020 Q4	$31.3M	Buy	2,885,300 +10,000	+0.3%	+$103K	15.82%	3
2020 Q3	$27.9M	Hold	2,875,300	–	–	17.4%	2
2020 Q2	$22.9M	Buy	2,875,300 +5,000	+0.2%	+$51.6K	16.87%	2
2020 Q1	$24.9M	Hold	2,870,300	–	–	23.66%	1
2019 Q4	$32.5M	Hold	2,870,300	–	–	21.66%	1
2019 Q3	$31.2M	Buy	2,870,300 +75,000	+3%	+$816K	16.6%	2
2019 Q2	$26.2M	Buy	2,795,300 +60,000	+2%	+$606K	13.43%	2
2019 Q1	$33.6M	Buy	2,735,300 +52,900	+2%	+$646K	15.95%	1
2018 Q4	$31.8M	Hold	2,682,400	–	–	16.11%	1
2018 Q3	$38.6M	Hold	2,682,400	–	–	16.11%	1
2018 Q2	$40M	Hold	2,682,400	–	–	14.76%	1
2018 Q1	$35M	Hold	2,682,400	–	–	12.18%	1
2017 Q4	$33.8M	Hold	2,682,400	–	–	11.66%	1
2017 Q3	$34.7M	Hold	2,682,400	–	–	12.43%	1
2017 Q2	$39.8M	Hold	2,682,400	–	–	13.28%	1
2017 Q1	$32.2M	Hold	2,682,400	–	–	11.79%	1
2016 Q4	$37M	Hold	2,682,400	–	–	13.33%	1
2016 Q3	$36M	Hold	2,682,400	–	–	12.03%	1
2016 Q2	$28.9M	Hold	2,682,400	–	–	10.45%	2
2016 Q1	$28.2M	Hold	2,682,400	–	–	11.06%	2
2015 Q4	$31.7M	Buy	2,682,400 +17,400	+0.7%	+$214K	10.73%	3
2015 Q3	$31.1M	Buy	2,665,000 +15,000	+0.6%	+$199K	12.45%	1
2015 Q2	$38.2M	Hold	2,650,000	–	–	14.72%	1
2015 Q1	$37M	Hold	2,650,000	–	–	16.34%	1
2014 Q4	$36.6M	Buy	2,650,000 +20,000	+0.8%	+$258K	15.41%	1
2014 Q3	$30M	Buy	2,630,000 +915,600	+53%	+$11.4M	13.89%	1
2014 Q2	$21.4M	Hold	1,714,400	–	–	9.86%	3
2014 Q1	$19.1M	Buy	1,714,400 +76,414	+5%	+$838K	9.34%	4
2013 Q4	$19.1M	Hold	1,637,986	–	–	8.57%	3
2013 Q3	$19.2M	Sell	1,637,986 -164,815	-9%	-$2.3M	7.23%	5
2013 Q2	$22.9M	Buy	+1,802,801	New	+$24.9M	8.59%	3

Other funds holding LFCR

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wynnefield Capital's LFCR Position: Q1 2026 in Review

Wynnefield Capital held its Lifecore Biomedical (LFCR) position steady in Q1 2026 at 4,703,216 shares worth $17.5M. The position accounts for 11.86% of the portfolio, ranked #4.

Wynnefield Capital first reported a position in LFCR in Q2 2013 and has held it in 52 quarters since. The position peaked at $47.6M in Q2 2023. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

Wynnefield Capital held 4,703,216 shares of Lifecore Biomedical worth $17.5M as of Q1 2026.
Wynnefield Capital left its Lifecore Biomedical share count unchanged in Q1 2026.
Lifecore Biomedical made up 11.86% of Wynnefield Capital's portfolio in Q1 2026, its #4 holding.
Wynnefield Capital first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 52 quarters since.
Wynnefield Capital's Lifecore Biomedical position peaked at $47.6M in Q2 2023.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Wynnefield Capital's 13F filing for Q1 2026, filed 15 May 2026.